Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling.

Momar Ndao, Terry W. Spithill, +8 authors Brian J Ward
Published 2010 in Journal of clinical microbiology

Abstract

More than 10 million people are thought to be infected with Trypanosoma cruzi, primarily in the Americas. The clinical manifestations of Chagas' disease (CD) are variable, but most subjects remain asymptomatic for decades. Only 15 to 30% eventually develop terminal complications. All current diagnostic tests have limitations. New approaches are needed for… (More)

DOI: 10.1128/JCM.02207-09

J. Gorlin, S.S.F. Rossmann, +7 authors H. Warren
Transfusion
2008

F. Fenollar, A. Goncalves, +4 authors D. Raoult
J. Infect. Dis
2006

Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling.

Abstract

Topics

8 Figures and Tables

Cited By

A family cluster of Chagas disease detected through selective screening of blood donors: A case report and brief review

Trypanosoma cruzi Infection and Host Lipid Metabolism

Aptamer Based, Non-PCR, Non-Serological Detection of Chagas Disease Biomarkers in Trypanosoma cruzi Infected Mice

Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review.

Biomarkers in Trypanosoma cruzi-Infected and Uninfected Individuals with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment

Delivering on promises? The Impact of Kinetoplastid Genomics on Sleeping Sickness, Chagas Disease and Leishmaniasis

Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis

Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect

References

Classification tree modeling to identify severe and moderate vehicular injuries in young and middle-aged adults

Applications of SELDI-MS technology in oncology

Discovery and validation of serum biomarkers expressed over the first twelve weeks of Fasciola hepatica infection in sheep.

Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening

Use of ProteinChip technology for identifying biomarkers of parasitic diseases: the example of porcine cysticercosis (Taenia solium).

Depletion of high-abundance proteins in plasma by immunoaffinity subtraction for two-dimensional difference gel electrophoresis analysis.

A serum protein signature with high diagnostic value in bacterial endocarditis: results from a study based on surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Chagas' disease--can we stop the deaths?

Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor

Field evaluation of four novel enzyme immunoassays for Chagas' disease in Venezuela blood banks: comparison of assays using fixed-epimastigotes, fixed-trypomastigotes or trypomastigote excreted-secreted antigens from two Trypanosoma cruzi strains.

Slides referencing similar topics

Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling.

Abstract

Topics

8 Figures and Tables

Cited By

A family cluster of Chagas disease detected through selective screening of blood donors: A case report and brief review

Trypanosoma cruzi Infection and Host Lipid Metabolism

Aptamer Based, Non-PCR, Non-Serological Detection of Chagas Disease Biomarkers in Trypanosoma cruzi Infected Mice

Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review.

Biomarkers in Trypanosoma cruzi-Infected and Uninfected Individuals with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment

Delivering on promises? The Impact of Kinetoplastid Genomics on Sleeping Sickness, Chagas Disease and Leishmaniasis

Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis

Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect

References

Classification tree modeling to identify severe and moderate vehicular injuries in young and middle-aged adults

Applications of SELDI-MS technology in oncology

Discovery and validation of serum biomarkers expressed over the first twelve weeks of Fasciola hepatica infection in sheep.

Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening

Use of ProteinChip technology for identifying biomarkers of parasitic diseases: the example of porcine cysticercosis (Taenia solium).

Depletion of high-abundance proteins in plasma by immunoaffinity subtraction for two-dimensional difference gel electrophoresis analysis.

A serum protein signature with high diagnostic value in bacterial endocarditis: results from a study based on surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Chagas' disease--can we stop the deaths?

Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor

Field evaluation of four novel enzyme immunoassays for Chagas' disease in Venezuela blood banks: comparison of assays using fixed-epimastigotes, fixed-trypomastigotes or trypomastigote excreted-secreted antigens from two Trypanosoma cruzi strains.

Similar Papers

Slides referencing similar topics